Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) shares rose 6.9% on Wednesday. The company traded as high as $3.24 and last traded at $3.2080. Approximately 117,451 shares were traded during trading, a decline of 87% from the average daily volume of 935,515 shares. The stock had previously closed at $3.00.
Analysts Set New Price Targets
ENTX has been the subject of several recent analyst reports. Lifesci Capital initiated coverage on Entera Bio in a report on Wednesday, September 23rd. They issued an "outperform" rating and a $10.00 target price for the company. Cantor Fitzgerald assumed coverage on Entera Bio in a report on Tuesday, September 22nd. They set an "overweight" rating on the stock. Wall Street Zen cut Entera Bio from a "sell" rating to a "strong sell" rating in a research report on Saturday, November 7th. UBS Group set a $9.00 price objective on Entera Bio in a research note on Friday, September 18th. Finally, Leerink Partners began coverage on Entera Bio in a research report on Friday, September 18th. They set an "outperform" rating and a $9.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $9.60.
Check Out Our Latest Stock Report on Entera Bio
Entera Bio Stock Up 8.2%
The firm has a 50 day moving average of $2.90 and a 200 day moving average of $2.01. The firm has a market cap of $565.08 million, a PE ratio of -8.32 and a beta of 1.48.
Entera Bio (NASDAQ:ENTX - Get Free Report) last announced its quarterly earnings data on Friday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.05). On average, research analysts anticipate that Entera Bio Ltd. will post -0.40 EPS for the current year.
Hedge Funds Weigh In On Entera Bio
A number of large investors have recently modified their holdings of the company. Seven Fleet Capital Management LP grew its position in Entera Bio by 51.9% during the first quarter. Seven Fleet Capital Management LP now owns 205,542 shares of the company's stock worth $228,000 after buying an additional 70,224 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Entera Bio in the third quarter worth approximately $613,000. Renaissance Technologies LLC raised its stake in Entera Bio by 338.4% in the first quarter. Renaissance Technologies LLC now owns 473,442 shares of the company's stock valued at $526,000 after purchasing an additional 365,441 shares in the last quarter. Nantahala Capital Management LLC purchased a new stake in Entera Bio in the third quarter valued at approximately $8,744,000. Finally, RA Capital Management L.P. bought a new stake in Entera Bio during the third quarter valued at approximately $14,265,000. 14.11% of the stock is currently owned by institutional investors.
Entera Bio Company Profile
(
Get Free Report)
Entera Bio Ltd. is a clinical-stage biopharmaceutical company based in Jerusalem, Israel. It develops oral peptide therapies for conditions that have traditionally been treated with injectable medicines, with a focus on bone and endocrine disorders. The company's development programs include EB613, an oral formulation of parathyroid hormone being studied for osteoporosis, and EB612, an oral parathyroid hormone candidate for hypoparathyroidism. Entera uses its proprietary oral-delivery technology to pursue the development of these therapies.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Entera Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.
While Entera Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.